Focal secondary malignant liver lesions: MnDPDP-enhanced MRT at 0.2 Tesla vs. Helical CT-arterioportography;Fokale maligne sekundäre leberläsionen: Manganverstärkte niederfeld-MRT bei 0,2 tesla versus spirai-CT-arterioportographie

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 174, Issue 11, 2002, Pages 1402-1407

  Rieger, J ^a   Korner M ^a   Linsenmaier, U ^a   Rock, C ^a   Wirth, S ^a   Pfeifer, K J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Contrast media; Liver lesions; Low field MRT; MnDPDP CT AP; Open MR scanner

Indexed keywords

MANGAFODIPIR;

ADULT; AGED; ARTICLE; CANCER SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELIABILITY;

ADULT; AGED; CONTRAST MEDIA; EDETIC ACID; FEMALE; HUMANS; IMAGE ENHANCEMENT; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PORTOGRAPHY; PROSPECTIVE STUDIES; PYRIDOXAL PHOSPHATE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 18744415028     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35337     Document Type: Article

References (21)

1. Hisa N, Hiramatsu K, Narimatsu Y, Watanabe M, Tanida I. (Detection of hepatic neoplasms by computed tomography in portal hepatogram phase [author's transl]). Rinsho Hoshasen 1980; 25: 529-534
2. Soyer P, Bluemke DA, Fishman EK. CT during arterial portography for the preoperative evaluation of hepatic tumors: How, when, and why? Am J Roentgenol 1994; 163: 1325-1331
3. Helmberger H, Bautz W, Vogel U, Lenz M. CT arterioportography in the spiral technic for the demonstration of liver metastases. Fortschr Röntgenstr 1993; 158: 410-415
4. Kanematsu M, Imaeda T, Hopshi H, Yokoyama R, Mizuno S. Methodological assessment of combined spiral CT angiography and CT arterial portography. Abdom Imaging 1997; 22: 404-409
5. Bluemke DA, Fishman EK. Spiral CT arterial portography of the liver. Radiology 1993; 186: 576-579
6. Soyer P. CT during arterial portography. Eur Radiol 1996; 6: 349-357
7. Semelka RC, Schlund JF, Molina PL, et al. Malignant liver lesions: Comparison of spiral CT arterial portography and MR imaging for diagnostic accuracy, cost, and effect on patient management. J Magn Reson Imaging 1996; 6: 39-43
8. Semelka RC, Cance WG, Marcos HB, Mauro MA. Liver metastases: Comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology 1999; 213: 86-91
9. Torres CG, Lundby B, Sterud AT, McGill S, Gordon PB, Bjerknes HS. MnDPDP for MR imaging of the liver. Results from the European phase III studies (see comments). Acta Radiol 1997; 38: 631-637
10. Wang C, Ahlstrom H, Ekholm S, et al. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study (see comments). Acta Radiol 1997; 38: 643-649
11. Kane PA, Ayton V, Walters HL, et al. MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings (see comments). Acta Radiol 1997; 38: 650-654
12. Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996; 200: 69-77
13. Rummeny EJ, Torres CG, Kurdziel JC, Nilsen G, Op DB, Lundby B. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies (see comments). Acta Radiol 1997; 38: 638-642
14. Federle M, Chezmar J, Rubin DL, Weinreb J, Freeny P, Schmiedl UP, Brown JJ, Borrello JA, Lee JK, Semelka RC, Mattrey R, Dachman AH, Saini S, Harms SE, Mitchell DG, Anderson MW, Halford 3rd HH, Bennett WF, Young SW, Rifkin M, Gay SB, Ballerini R, Sherwin PF, Robison RO. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection of hepatic MR1 in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging. J Magn Reson Imaging 2000; 12 (5): 689-701
15. Larsen LE, Grant D. General toxicology of MnDPDP. Acta Radiol 1997; 38: 770-779
16. Toft KG, Hustvedt SO, Grant D, et al. Metabolism and pharmacokinetics of MnDPDP in man (see comments). Acta Radiol 1997; 38: 677-689
17. Padovani B, Lecesne R, Raffaelli C, et al. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 μmol/kg body weight in detecting focal liver tumors: Results of a phase III trial using an infusion technique. Eur J Radiol 1996; 23: 205-211
18. Helmberger T, Gregor M, Holzknecht N, Rau H, Scheidler J, Reiser M. Effects of biphasic spiral CT, conventional and iron oxide enhanced MR1 on therapy and therapy costs in patients with focal liver lesions. Fortschr Röntgenstr 2000; 172 (3): 251-259
19. Trattnig S, Kontaxis G, Breitenseher M, et al. MRI on low-field tomography systems (0.2 Tesla). A quantitative comparison with equipment of medium-field strength (1.0 Tesla). Radiologe 1997; 37: 773-777
20. Martí-Bonmatí L, Kormano M. MR equipment acquisition strategies: Low-field or high-field scanners. Eur Radiol 1997; 7 (5): 263-268
21. Deckers F, Corthouts B, Nackaerts Y, Ozsarlak O, Parizel PM, De Schepper AM. The influence of MR field strength on the detection of focal liver lesions with superparamagnetic iron oxide. Eur Radiol 1997; 7: 887-892